Print

HVTN 703 AMP

A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa

Trial Details:

IIb Ongoing
National Institute of Allergy and Infectious Diseases (NIAID) April 01, 2016
VRC-HIVMAB060-00-AB VRC01 Antibody
VRC-HIVMAB060-00-AB Passive Immunization
South Africa, Kenya, Malawi, Mozambique, Tanzania, Botswana 1500
NCT02568215
https://clinicaltrials.gov/ct2/show/NCT02568215